Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Heartflow, Inc.HTFL · Entity 3993 | Chief Medical Officer | September 18, 2026 | September 21, 2026 |
| InspireMD, Inc.NSPR · Entity 7318 | Director | October 13, 2021 | October 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Heartflow, Inc.
Report date September 18, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,956 |
Ending reported balance
After 2026-09-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-18 · Exercise / conversion · Acquired 12,329 · Balance 98,788 F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. Row 2 · 2026-09-18 · Exercise / conversion · Acquired 850 · Balance 99,638 F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. Row 3 · 2026-09-18 · Sale · Disposed 19,682 · Balance 79,956 F2: Includes the sale of 6,503 shares of common stock held and the option exercise and sale of 13,179 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.33 · Expires 2030-02-28 | Direct | 31,456 |
Reported balance
After 2026-09-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-18 · Exercise / conversion · Disposed 12,329 · Balance 31,456 F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. F3: These stock options are fully exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2033-07-10 | Direct | 70,783 |
Reported balance
After 2026-09-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-18 · Exercise / conversion · Disposed 850 · Balance 70,783 F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. F4: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Campbell Rogers 2019 Irrevocable Trust | 22,615 |
Reported balance
Holding disclosure · report date 2026-09-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 22,615 |
| Common StockSEC Table I · non-derivative | IndirectBy CR Asset Protection Trust of 2023 | 46,159 |
Reported balance
Holding disclosure · report date 2026-09-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 46,159 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse's Trust | 26,012 |
Reported balance
Holding disclosure · report date 2026-09-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 26,012 |
| Common StockSEC Table I · non-derivative | IndirectBy The Campbell Rogers Revocable Trust | 50,754 |
Reported balance
Holding disclosure · report date 2026-09-18 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 50,754 |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
F2: Includes the sale of 6,503 shares of common stock held and the option exercise and sale of 13,179 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
F3: These stock options are fully exercisable.
F4: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.
InspireMD, Inc.
Report date October 13, 2021 · Filed October 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,960 |
Reported balance
After 2021-10-13 transaction · row 1
1 source rowRow 1 · 2021-10-13 · Grant · Acquired 17,248 · Balance 27,960 F1: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service. |
| Options to purchase common stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2031-10-13 | Direct | 5,749 |
Reported balance
After 2021-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-10-13 · Grant · Acquired 5,749 · Balance 5,749 F2: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service.
F2: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Corindus Vascular Robotics, Inc.
Report date October 29, 2019 · Filed October 31, 2019
Section 16 reporting ended · disclosed 2019-10-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 1
1 source rowRow 1 · 2019-10-29 · Disposition to issuer · Disposed 90,149 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: These shares represent 69,412 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2026-02-03 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-29 · Disposition to issuer · Disposed 98,522 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2026-09-26 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-29 · Disposition to issuer · Disposed 27,272 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-29 · Disposition to issuer · Disposed 17,857 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: These shares represent 69,412 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes.
F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant.
F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes.
F6: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 21, 2026 22:19 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 850 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001464521-26-000152 · form4.xml · derivative · entry 9 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,783 Underlying: Common Stock · 850 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. F4 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. Read SEC document |
| September 18, 2026 Filed Sep 21, 2026 22:19 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 12,329 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001464521-26-000152 · form4.xml · derivative · entry 8 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,456 Underlying: Common Stock · 12,329 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. F3 · derivative.exercise_date: These stock options are fully exercisable. Read SEC document |
| September 18, 2026 Filed Sep 21, 2026 22:19 UTC | Heartflow, Inc. HTFL · Entity 3993 | SaleCommon Stock | 19,682 | $50.15 | $987,052.30 |
DisclosureSEC source: 0001464521-26-000152 · form4.xml · nonDerivative · entry 3 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,956 F2 · kind: Includes the sale of 6,503 shares of common stock held and the option exercise and sale of 13,179 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. Read SEC document |
| September 18, 2026 Filed Sep 21, 2026 22:19 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 850 | $2.22 | $1,887.00 |
DisclosureSEC source: 0001464521-26-000152 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. Read SEC document |
| September 18, 2026 Filed Sep 21, 2026 22:19 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 12,329 | $8.33 | $102,700.57 |
DisclosureSEC source: 0001464521-26-000152 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 01:04 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Options · Derivative | 9,219 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001464521-26-000135 · form4.xml · derivative · entry 7 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,972 Underlying: Common Stock · 9,219 shares Expires 2035-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. F2 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until August 7, 2029, subject to continued service through the applicable vesting date. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 01:04 UTC | Heartflow, Inc. HTFL · Entity 3993 | SaleCommon Stock | 9,219 | $41.23 | $380,099.37 |
DisclosureSEC source: 0001464521-26-000135 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,459 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 01:04 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 9,219 | $19.00 | $175,161.00 |
DisclosureSEC source: 0001464521-26-000135 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. Read SEC document |
| August 07, 2026 Filed Aug 10, 2026 21:17 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock | 637 | $28.82 | $18,358.34 |
DisclosureSEC source: 0001464521-26-000119 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,459 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 21:17 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock | 1,635 | $27.19 | $44,455.65 |
DisclosureSEC source: 0001464521-26-000119 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,096 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 21:54 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Options · Derivative | 9,219 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001464521-26-000103 · form4.xml · derivative · entry 7 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,191 Underlying: Common Stock · 9,219 shares Expires 2035-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. F2 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until August 7, 2029, subject to continued service through the applicable vesting date. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 21:54 UTC | Heartflow, Inc. HTFL · Entity 3993 | SaleCommon Stock | 9,219 | $25.72 | $237,112.68 |
DisclosureSEC source: 0001464521-26-000103 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,731 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 21:54 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 9,219 | $19.00 | $175,161.00 |
DisclosureSEC source: 0001464521-26-000103 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:39 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001464521-26-000078 · form4.xml · derivative · entry 6 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,633 Underlying: Common Stock · 10,000 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. F2 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 21:39 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 10,000 | $2.22 | $22,200.00 |
DisclosureSEC source: 0001464521-26-000078 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:55 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Options · Derivative | 9,219 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001464521-26-000073 · form4.xml · derivative · entry 7 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,410 Underlying: Common Stock · 9,219 shares Expires 2035-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. F2 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until August 7, 2029, subject to continued service through the applicable vesting date. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:55 UTC | Heartflow, Inc. HTFL · Entity 3993 | SaleCommon Stock | 9,219 | $28.34 | $261,266.46 |
DisclosureSEC source: 0001464521-26-000073 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,731 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:55 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 9,219 | $19.00 | $175,161.00 |
DisclosureSEC source: 0001464521-26-000073 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 12, 2025. Read SEC document |
| May 07, 2026 Filed May 8, 2026 22:45 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock | 637 | $29.98 | $19,097.26 |
DisclosureSEC source: 0001464521-26-000061 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,731 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| May 06, 2026 Filed May 8, 2026 22:45 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock | 1,634 | $30.29 | $49,493.86 |
DisclosureSEC source: 0001464521-26-000061 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,368 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:15 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 40,766 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001464521-26-000052 · form4.xml · derivative · entry 13 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,633 Underlying: Common Stock · 40,766 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F6 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:15 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 19,111 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001464521-26-000052 · form4.xml · derivative · entry 12 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,399 Underlying: Common Stock · 19,111 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F6 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:15 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 291 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001464521-26-000052 · form4.xml · derivative · entry 11 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,298 Underlying: Common Stock · 291 shares Expires 2031-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F5 · derivative.exercise_date: These stock options are fully exercisable. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:15 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Options · Derivative | 6,849 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001464521-26-000052 · form4.xml · derivative · entry 10 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,849 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F5 · derivative.exercise_date: These stock options are fully exercisable. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:15 UTC | Heartflow, Inc. HTFL · Entity 3993 | SaleCommon Stock | 64,533 | $24.64 | $1,590,093.12 |
DisclosureSEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 5 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,002 F3 · kind: Includes the sale of 16,918 shares of common stock held and the option exercise and sale of 47,615 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F4 · price: This transaction was executed in multiple trades at price ranging from $24.03 to $25.27. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:15 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 6,849 | $2.22 | $15,204.78 |
DisclosureSEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 4 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:15 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 40,766 | $2.22 | $90,500.52 |
DisclosureSEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 3 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:15 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 19,111 | $2.22 | $42,426.42 |
DisclosureSEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:15 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 291 | $8.33 | $2,424.03 |
DisclosureSEC source: 0001464521-26-000052 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 22:33 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 47,615 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001464521-26-000048 · form4.xml · derivative · entry 9 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,510 Underlying: Common Stock · 47,615 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F5 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 22:33 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 19,402 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001464521-26-000048 · form4.xml · derivative · entry 8 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,125 Underlying: Common Stock · 19,402 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F5 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 22:33 UTC | Heartflow, Inc. HTFL · Entity 3993 | SaleCommon Stock | 64,533 | $25.69 | $1,658,033.46 |
DisclosureSEC source: 0001464521-26-000048 · form4.xml · nonDerivative · entry 3 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,518 F3 · kind: Includes the sale of 16,918 shares of common stock held and the option exercise and sale of 47,615 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F4 · price: This transaction was executed in multiple trades at price ranging from $25.00 to $28.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 22:33 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 47,615 | $2.22 | $105,705.30 |
DisclosureSEC source: 0001464521-26-000048 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 22:33 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 19,402 | $2.22 | $43,072.44 |
DisclosureSEC source: 0001464521-26-000048 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:07 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 7,906 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001464521-26-000018 · form4.xml · derivative · entry 11 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,527 Underlying: Common Stock · 7,906 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F6 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:07 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 19,401 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001464521-26-000018 · form4.xml · derivative · entry 10 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,433 Underlying: Common Stock · 19,401 shares Expires 2033-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F6 · derivative.exercise_date: The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:07 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionStock Option · Derivative | 39,709 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001464521-26-000018 · form4.xml · derivative · entry 9 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,709 shares Expires 2026-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F5 · derivative.exercise_date: These stock options are fully exercisable. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:07 UTC | Heartflow, Inc. HTFL · Entity 3993 | SaleCommon Stock | 65,153 | $24.49 | $1,595,486.21 |
DisclosureSEC source: 0001464521-26-000018 · form4.xml · nonDerivative · entry 4 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,034 F3 · kind: Includes the sale of 17,538 shares of common stock held and the option exercise and sale of 47,615 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. F4 · price: This transaction was executed in multiple trades at price ranging from $22.90 to $26.51. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:07 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 7,906 | $2.22 | $17,551.32 |
DisclosureSEC source: 0001464521-26-000018 · form4.xml · nonDerivative · entry 3 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:07 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 39,709 | $8.33 | $330,775.97 |
DisclosureSEC source: 0001464521-26-000018 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:07 UTC | Heartflow, Inc. HTFL · Entity 3993 | Exercise / conversionCommon Stock | 19,401 | $2.22 | $43,070.22 |
DisclosureSEC source: 0001464521-26-000018 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 01:21 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantStock Option · Derivative | 94,488 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001464521-26-000012 · form4.xml · derivative · entry 7 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,488 Underlying: Common Stock · 94,488 shares Expires 2036-02-06 F3 · derivative.exercise_date: The option vests 1/48 on each monthly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 01:21 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantCommon Stock | 54,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001464521-26-000012 · form4.xml · nonDerivative · entry 2 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,171 F2 · shares: Represents restricted stock units ("RSUs"), with a vesting commencement date of February 6, 2026 (the "Vesting Commencement Date"). 1/16th of the RSUs vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 01:21 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock | 515 | $27.74 | $14,286.10 |
DisclosureSEC source: 0001464521-26-000012 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,098 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| November 07, 2025 Filed Nov 13, 2025 01:46 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock | 439 | $32.56 | $14,293.84 |
DisclosureSEC source: 0001464521-25-000033 · form4.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,613 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| August 07, 2025 Filed Aug 12, 2025 01:01 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantStock Options · Derivative | 110,629 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001628280-25-039733 · wk-form4_1754960459.xml · derivative · entry 6 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,629 Underlying: Common Stock · 110,629 shares Expires 2035-08-07 F2 · derivative.exercise_date: The option vests 1/48 on each monthly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. Read SEC document |
| August 07, 2025 Filed Aug 12, 2025 01:01 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantCommon Stock | 21,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-039733 · wk-form4_1754960459.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,052 F1 · shares: Represents restricted stock units ("RSUs"), with a vesting commencement date of August 7, 2025 (the "Vesting Commencement Date"). 1/16th of the RSUs vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. Read SEC document |
| October 13, 2021 Filed Oct 14, 2021 21:00 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 5,749 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001493152-21-025451 · ownership.xml · derivative · entry 2 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,749 Underlying: Common Stock · 5,749 shares Expires 2031-10-13 F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service. Read SEC document |
| October 13, 2021 Filed Oct 14, 2021 21:00 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 17,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-025451 · ownership.xml · nonDerivative · entry 1 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,960 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of October 13, 2022, October 13, 2023 and October 13, 2024, subject to the Reporting Person's continued service. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:55 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 52,678 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001493152-20-017125 · ownership.xml · derivative · entry 2 Rogers Campbell · CIK 0001585724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,692 Underlying: Common Stock · 52,678 shares Expires 2030-08-31 F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of August 31, 2021, August 31, 2022 and August 31, 2023, subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.